MASS vs MGTX: fair value comparison
908 Devices Inc. and MeiraGTx Holdings plc · Updated 2026-10-19
MASS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. MGTX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, MGTX currently ranks higher by quality score.
| MASS | MGTX | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $11.26 | $9.28 |
| 12-month range | $5.09–$12.80 | $6.99–$14.97 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #92 of 301 Healthcare | #90 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Moderate |
| Margin trend | Stable | Contracting |
| Revenue growth | Modest | — |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Uptrend | Mixed |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: MASS fair value analysis · MGTX fair value analysis